World Journal of Pharmaceutical
Science and Research

A Global Platform for Open Access, Peer-Reviewed, and Indexed Research in the
Pharmaceutical and Medical Sciences


Login | Registration


ISSN: 2583-6579


Impact Factor: 5.111

ABSTRACT

POLYCYSTIC OVARY SYNDROME (PCOS) WITH PATHOPHYSIOLOGY AND EMERGING THERAPIES

Nahida Tabassum* and Rameshwar Kumar

Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder that affects approximately 8–13% of women of reproductive age worldwide, depending on the diagnostic criteria and population studied.[1] Clinically, it is defined by the presence of hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, after exclusion of other related conditions.[2] PCOS is associated with significant reproductive, metabolic, and psychological complications, extending far beyond fertility concerns. Insulin resistance, present even in lean phenotypes, plays a central role in amplifying hyperandrogenism and disrupting folliculogenesis, ultimately leading to chronic anovulation.[3] This interplay contributes to long-term consequences including obesity, type 2 diabetes mellitus, dyslipidaemia, cardiovascular risk, and an increased likelihood of endometrial pathology.[4] Over the past decade, advances in research and international guideline updates have shaped the diagnostic framework and therapeutic strategies for PCOS. The 2023 International Evidence-Based Guideline reaffirmed the Rotterdam criteria for adults, clarified adolescent diagnostic parameters, and emphasized the role of anti-Müllerian hormone (AMH) as a marker of polycystic ovarian morphology in adults, but not as a stand-alone diagnostic test.[5] Management continues to rely on lifestyle modification as the cornerstone of therapy, combined oral contraceptives for cycle regulation and hyperandrogenism, and letrozole as first-line pharmacological treatment for anovulatory infertility. Metformin remains an important adjunct for insulin resistance and metabolic risk reduction. In recent years, novel pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium–glucose cotransporter 2 (SGLT2) inhibitors have demonstrated promise in improving metabolic parameters and weight management, though further large-scale studies are required to confirm their long-term safety and reproductive benefits. This review explores the pathophysiological mechanisms underlying PCOS, synthesizes existing literature, and evaluates current and emerging therapeutic options with a focus on clinical translation and future research directions.

[Full Text Article]

TRACK ARTICLE

NEWS

  • Impact Factor Increased

    We are pleased to inform you that our IMPACT FACTOR has increased from 3.454 to 5.111

    Email & SMS Alert

    We will provide you email alerts regarding New Issue Release, Publication of your Article, Invitaion for New Upcoming Issue, Manuscript releted Emails etc.

    August 2025 Issue Published

    Its Our pleasure to inform you that, WJPSR August 2025 Issue has been Published, Kindly check it on Click here

    Indexing

    This journal is indexed in world wide reputed commettee like: "DOI for all Articles" "Google Scholer" "SJIF Impact Factor:- 5.111" "Cosmos Impact Factor" "ISI Indexing" "International Impact Factor Services (IIFS)" "ResearchBib" etc.

    Article Invite for Publication

    Dear Researcher, Article Invited for Publication  in WJPSR Coming Issue.

    If you wish to Publish your Article in WJPSR Coming " August 2025 " Issue, 

    Submit it as soon as possible.